Clinical trials: Intravenous Administration
Pneumonia
Zithromax EV in Community-Acquired Pneumonia (CAP)
The intravenous (IV) regimen containing azithromycin (Zithromax) plus ampicillin-sulbactam is consistent with current guidelines for the treatment of CAP.
- Trial name
- NCT00137007
- Testing
- Azithromycin, Ampicillin/sulbactam
- Volunteers
- 151 people
- Sponsor
- Pfizer
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.
This study will evaluate the safety and tolerability of PEGASYS plus ribavirin in previous intravenous (iv) drug users who have CHC and are currently enrolled in a methadone maintenance treatment program.
- Trial name
- NCT00087594
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
Antimycotic for Systematic Use
Evaluate Bioequivalence of Voriconazole(200mg/Vial) .
A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Voriconazole(200mg/Vial) After Intravenous Infusion of 200mg Voriconazole in Healthy Volunteers Under Fasting Conditions.
- Trial name
- NCT04552353
- Testing
- Vaway
- Where
- Taiwan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
Pulmonary Disease, Chronic Obstructive
A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719
This will be a two-period, open-label study conducted at a single site. Six healthy male subjects will participate in the study to ensure at least four fully evaluable subjects.
- Trial name
- NCT01362257
- Testing
- Treatment Period 1 - IV dose of GSK573719, Treatment Period 2 - Oral dose of GSK573719
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Muscular Dystrophies
A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of Administration
The purpose of the extension phase of this study is to determine whether Drisapersen is effective in the treatment of boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping.
- Trial name
- NCT01910649
- Testing
- Drisapersen
- Volunteers
- 12 people
- Sponsor
- BioMarin Pharmaceutical
Colorectal Carcinoma
Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver Resection
This is a neoadjuvant Phase 2a, open-label trial in patients with metastatic colorectal carcinoma who are undergoing a complete resection of the metastatic colorectal tumors in their liver.
- Trial name
- NCT01329809
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Jennerex Biotherapeutics
Sedation
A Study Evaluating the Efficacy and Safety of HSK3486 for Sedation
This is a multi-center, open-label, randomized, propofol-controlled phase II clinical trial.A total of ICU patients undergoing mechanical ventilation are intended to be enrolled and randomly assigned to HSK3486 group and propofol…
- Trial name
- NCT04147416
- Testing
- HSK3486 0.1-0.2 /0.3 mg / kg group, Propofol 0.5-1.0/1.5 mg/kg group
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Melanoma
A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma
The primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.
- Trial name
- SUMMIT-1 (NCT01006252)
- Testing
- Tasisulam-sodium, Paclitaxel
- Where
- 122 sites in United States, Australia and 16 more
- Volunteers
- 336 people
- Sponsor
- Eli Lilly and Company
Pharmacokinetics, Inhibition Enzyme
Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1
The purpose of the study is: to determine absolute bioavailability, input rates, distribution volume, renal and intestinal excretion of trospium in subjects with wild-type of SLC22A1 rs72552763 and rs12208357 and in subjects with…
- Conditions
- Pharmacokinetics, Inhibition Enzyme, Drug Interaction Potentiation
- Trial name
- NCT03011463
- Testing
- intravenous infusion of 2 mg trospium chloride, oral administration of 30 mg trospium chloride, oral administration of 300 mg ranitidine
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Dr. R. Pfleger Chemische Fabrik GmbH
Soft Tissue Infections
Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections
This is a Phase 4, randomized, open-label, multicenter, comparative study designed to further evaluate the pharmacokinetics of intravenous (i.v.) daptomycin and the safety and efficacy of daptomycin relative to comparator in the…
- Trial name
- NCT00102947
- Testing
- daptomycin (up to 14 days)
- Where
- 12 sites in United States
- Volunteers
- 72 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Patent Ductus Arteriosus
Safety and Efficacy Study of Ibuprofen l-Lysine Solution in Premature Infants for Treatment of PDA
The purpose of this study is to determine the safety and effectiveness of ibuprofen l-lysine iv in premature infants in the early treatment of Patent Ductus Arteriosus.
- Trial name
- NCT00440804
- Testing
- ibuprofen l-lysine iv solution (NeoProfen (R) )
- Sponsor
- Farmacon
Primary Amyloidosis
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30 subjects with AL amyloidosis. Expansion phase to evaluate safety, efficacy and pharmacokinetics of NEOD001 in 25 additional subjects at…
- Trial name
- NCT01707264
- Testing
- NEOD001
- Where
- 7 sites in United States
- Volunteers
- 69 people
- Sponsor
- Prothena Biosciences Ltd.
Acute Pain
Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery
The purpose of this study is to determine the effectiveness and safety of single intravenous doses of the kappa opioid agonist CR845 in relieving pain in patients following laparoscopic-assisted hysterectomy surgery.
- Trial name
- NCT00877799
- Testing
- CR845
- Where
- 12 sites in United States
- Volunteers
- 114 people
- Sponsor
- Cara Therapeutics, Inc.
Pain, Acute Pain
A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults
This study will be a single-center, double-blind, randomized placebo-controlled, adaptive, single ascending dose study.
- Trial name
- NCT05721287
- Testing
- SBS-1000
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sparian Biosciences, Inc
Chronic Obstructive Pulmonary Disease
Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells
This phase II study is a randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of UMC119-06-05 compared to placebo in treating subjects with moderate to severe COPD.
- Trial name
- NCT06491043
- Testing
- UMC119-06-05
- Where
- 2 sites in Taiwan
- Volunteers
- 90 people
- Sponsor
- Meribank Biotech Co., Ltd.
Melanoma
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
The purpose of this study is to assess the safety and tolerability of subcutaneous nivolumab vs intravenous nivolumab in participants with completely resected Stage IIIA/B/C/D or Stage IV melanoma.
- Trial name
- CheckMate-6GE (NCT05297565)
- Testing
- Nivolumab/rHuPH20, Nivolumab
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 14 people
- Sponsor
- Bristol-Myers Squibb
Friedreich's Ataxia (FA)
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
This is a phase 1b, first in-human, open-label, dose-finding study investigating the safety and tolerability of SGT-212 in participants with Friedreich's ataxia (FA).
- Trial name
- FALCON (NCT07180355)
- Testing
- SGT-212
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Solid Biosciences Inc.
ADME
Mass Balance Study of [14C]Xeruborbactam (QPX7728) in Healthy Adult Male Participants
This is a single-dose, phase 1 open-label study to determine the mass balance recovery and metabolic profiling and identification for intravenous (IV) administered [14C]xeruborbactam.
- Trial name
- NCT07083817
- Testing
- [14C]Xeruborbactam
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Neoplasm Malignant
Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients
Primary Objective: In the dose escalation: to determine the maximum tolerated dose (MTD) of SAR125844. In the expansion cohort: to evaluate the preliminary anti-tumoral effect of SAR125844 in patients with measurable and MET gene…
- Trial name
- SARMETA (NCT01657214)
- Testing
- SAR125844
- Where
- 8 sites in Japan, South Korea
- Volunteers
- 70 people
- Sponsor
- Sanofi
Postoperative Gastrointestinal Dysfunction
A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery
The main aim of this study is to check for side effects from TAK-954 and whether it speeds up the recovery of gastrointestinal function after small-bowel or large-bowel resection surgery.
- Trial name
- NCT03827655
- Testing
- TAK-954
- Where
- 25 sites in United States, Germany
- Volunteers
- 209 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.